Table 1. Patient characteristics (n=9).
| Characteristics | Values |
|---|---|
| Sex | |
| Male | 5 [56] |
| Female | 4 [44] |
| Age at baseline (years), median [range] | 53 [37–80] |
| Smoking history | |
| Current | 1 [11] |
| Former | 2 [22] |
| Never | 6 [67] |
| Histology | |
| Adenocarcinoma | 9 [100] |
| Others | 0 [0] |
| Clinical stage | |
| IV | 9 [100] |
| Others | 0 [0] |
| No. of treatments† | |
| 1 | 1 [11] |
| 2 | 4 [44] |
| 3 | 1 [11] |
| ≥4 | 3 [33] |
| No. of ALK TKI treatments | |
| 1 | 3 [33] |
| 2 | 3 [33] |
| 3 | 2 [22] |
| 4 | 1 [11] |
| No. of cytotoxic chemotherapy‡ treatments | |
| 0 | 5 [56] |
| 1 | 3 [33] |
| 2 | 1 [11] |
Data are presented as n [%] unless otherwise stated. †, treatments include ALK TKI, chemotherapy, and immune checkpoint inhibitors; ‡, cytotoxic chemotherapy: pemetrexed +/−, cisplatin or carboplatin +/−, bevacizumab +/−, and/or pembrolizumab +/−. ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor.